TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01756573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study: NCT00759876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with milk. Dosing based on participant body weight
Study: NCT01318928

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazol
Description: metronidazol. 400mg x 3 per day for 10 days
Study: NCT04576260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia
Description: Weekly CBTI training
Study: NCT03531762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of 500 mg Tepotinib in Treatment A, B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants received omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment B and C.
Study: NCT04709094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan was dosed as 2 x 100 milligram (mg) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan was dosed as 2 x 100 milligram (mg) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Danicopan was dosed as 2 x 100 milligram (mg) tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin was dosed as 2 x 10 mg and 1 x 5 mg warfarin sodium tablets (Coumadin or generic equivalent).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion was dosed as Wellbutrin (or generic equivalent) as 1 x 100 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol/Norethindrone
Description: EE/NET (0.035 mg/1 mg) was dosed as Ortho-Novum-1/35 (or generic equivalent) fixed-dose combination tablets.
Study: NCT04052412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AraG
Description: All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AraG
Description: All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
Study: NCT04871386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT) exercises
Description: The ACT group received 14 (partially succeeding) daily exercises, with each of the following categories being focused twice: Acceptance, contact with the present moment, cognitive defusion, self as context, personal values and committed action. The exercises consisted of metaphors and questions for self-reflection, explanations about emotions and thoughts with techniques to handle them differently, as well as a body scan.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) exercises
Description: The PP group received 14 daily exercises that were derived from positive psychology interventions that have been proven effective in alleviating clinical symptoms and increasing subjective well-being. In detail, these were: Identifying positive emotions and ways to increase them; Enhancing pleasure from daily activities; Writing a gratitude letter; Identifying and appreciating three personal traits; Receiving a letter of support from one's future self; Taking different perspectives on one's current situation; Envisioning a perfect day; Identifying energy boosters and drainers; Identifying 3 character strengths and using one in a new way; Life review: Writing a legacy; Identifying the positive relationships in one's life; Doing an act of kindness; Three good things; and Coping with failure.
Study: NCT00947089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxidized regenerated cellulose (Fibrillar SURGICEL)
Description: one gauze made of ORC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iodoform gauze
Description: one iodoform gauze
Study: NCT02143856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GLPG1205
Description: A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GLPG1205
Description: A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
Study: NCT00969605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two different modes for weaning from mechanical ventilation
Description: Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of two different modes for weaning from mechanical ventilation
Description: Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
Study: NCT02514811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Teen Outreach Program
Description: Students received the Teen Outreach Program as described previously.
Study: NCT03493061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
Study: NCT01719458

Intervention type: DRUG
Intervention: (S,S)-[11C]MRB
Description: PET radioligand

Intervention type: DRUG
Intervention: (S,S)-[11C]MRB
Description: PET radioligand

Intervention type: DRUG
Intervention: (S,S)-[11C]MRB
Description: PET radioligand
Study: NCT02088879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chest compression with kneeling position

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chest compression with kneeling position

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chest compression with standing position

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chest compression with standing position
Study: NCT01312805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA Asthma Module
Description: This module was added to CHICA to help diagnose and manage asthma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHICA Control
Description: This is CHICA without the asthma module, and was used as a control
Study: NCT03470740

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: rheumatoid arthritis self-management program
Description: The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
Study: NCT02793973

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shoe lifts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoe lifts
Study: NCT01166893

Intervention type: DEVICE
Intervention: Modulated Imaging and Laser Speckle Imaging
Description: wound healing
Study: NCT02402504

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Non pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small particle size pea flour
Description: Pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large particle size pea flour
Description: Pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lentil flour
Description: Pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navy bean flour
Description: Pulse extruded snack

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto bean flour
Description: Pulse extruded snack
Study: NCT04075747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Up to 2 induction and 2 consolidation courses will be offered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Up to 2 induction and 2 consolidation courses will be offered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Up to 2 induction and 2 consolidation courses will be offered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Will be administered over specified duration during induction and consolidation courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Will be administered over specified duration during induction and consolidation courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Will be administered over specified duration during induction and consolidation courses
Study: NCT04075006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
Study: NCT05245110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tele-exercise training
Description: a 12-week tele-exercise training program
Study: NCT03758131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-enhanced Motivational Interviewing
Description: In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer-enhanced Motivational Interviewing
Description: In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Control
Description: Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
Study: NCT01553682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Horizons+General Health Promotion (GHP)
Description: Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horizons+Motivational Enhancement Therapy (GMET)
Description: Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
Study: NCT02924441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Applied to breast skin
Study: NCT02051400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Macintosh laryngoscope
Study: NCT01485744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Description: LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
Study: NCT02135835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenfu Zhusheye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% glucose injection
Study: NCT04243083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablet, placebo
Description: Oral QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablet, placebo
Description: Oral QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablet, placebo
Description: Oral QD
Study: NCT03993782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A19010-R
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A19010-R
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B19010-O
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B19010-O
Description: A snus product
Study: NCT03839030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBHP-Educa
Description: This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
Study: NCT01119183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACOG education pamphlet on preeclampsia
Description: The ACOG pamphlet on preeclampsia will be offered to this group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preeclampsia education tool
Description: The newly created preeclampsia educational tool will be offered to this group
Study: NCT03885752

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chewed mint gum
Description: In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swallow twice
Description: asked to swallow twice without any additional treatment.
Study: NCT03101644

Intervention type: DRUG
Group type: OTHER
Intervention: Darunavir
Description: The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
Study: NCT01356264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimodal prehabilitation
Description: multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
Study: NCT02924441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Applied to breast skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Applied to breast skin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Applied to breast skin
Study: NCT00496054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pentavalent vaccine 9G1, G2, G3, G4 \& P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
Study: NCT02871700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Customary bilateral UE training
Description: The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
Study: NCT02521870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101(1)
Description: SD-101 administered intratumorally at escalating doses (up to 11 doses).
Study: NCT02924441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calming Music
Description: Played during mammography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calming Music
Description: Played during mammography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Music
Description: No music played during mammography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Music
Description: No music played during mammography
Study: NCT02579148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUCMSC injection
Description: The subjects will receive intracavernous injection of HUCMSC.'

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagen scaffolds/HUCMSC injection
Description: The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.'